Rasheedunnisa Begum

Dr. Rasheedunnisa Begum


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2013 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
NLNaresh C. Laddha
Naresh C. Laddha
MDMitesh Dwivedi
Mitesh Dwivedi
MMMohmmad S. Mansuri
Mohmmad S. Mansuri
AGAmina R. Gani
Amina R. Gani
ANAnsarullah
Ansarullah
RBRasheedunnisa Begum
Rasheedunnisa Begum

10 April 2013 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
MDMitesh Dwivedi
Mitesh Dwivedi
NLNaresh C. Laddha
Naresh C. Laddha
PAPrateek Arora
Prateek Arora
YMYogesh S. Marfatia
Yogesh S. Marfatia
RBRasheedunnisa Begum
Rasheedunnisa Begum

9 August 2011 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Closed access
PDF file
FSFranky D. Shah
Franky D. Shah
RBRasheedunnisa Begum
Rasheedunnisa Begum
BVBhairavi N. Vajaria
Bhairavi N. Vajaria
KPKinjal R. Patel
Kinjal R. Patel
JPJayendra B. Patel
Jayendra B. Patel
PPPrabhudas S. Patel
Prabhudas S. Patel

22 June 2016 in Cell Proliferation
Verified
Journal Article
Closed access
PDF file
TJT. Jubin
T. Jubin
AKA. Kadam
A. Kadam
MJM. Jariwala
M. Jariwala
SBS. Bhatt
S. Bhatt
SSS. Sutariya
S. Sutariya
RBRasheedunnisa Begum
Rasheedunnisa Begum

20 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NLNaresh C. Laddha
Naresh C. Laddha
MDMitesh Dwivedi
Mitesh Dwivedi
RBRasheedunnisa Begum
Rasheedunnisa Begum
Tumor Necrosis Factor (TNF)-α, is a paracrine inhibitor of melanocytes, which plays a critical role in the pathogenesis of several autoimmune diseases including vitiligo, as abnormal immune responses have frequently been observed in vitiligo patients. Moreover, vitiligo patients show higher lesion levels of TNF-α. Genetic polymorphisms in the promoter region of TNF-α are involved in the regulation of its expression. The present study explores TNF-α promoter polymorphisms and correlates them with TNF-α transcript and protein levels in vitiligo patients and controls of Gujarat along with its effect on disease onset and progression. PCR-RFLP technique was used for genotyping of these polymorphisms in 977 vitiligo patients and 990 controls. TNF-α transcript and protein levels were measured by Real time PCR and ELISA respectively. The genotype and allele frequencies for the investigated polymorphisms were significantly associated with vitiligo patients. The study revealed significant increase in TNF-α transcript and protein levels in vitiligo patients compared to controls. In particular, haplotypes: AATCC, AACCT, AGTCT, GATCT, GATCC and AGCCT were found to increase the TNF-α levels in vitiligo patients. Analysis of TNF-α levels based on the gender and disease progression suggests that female patients and patients with active vitiligo had higher levels of TNF-α. Also, the TNF-α levels were high in patients with generalized vitiligo as compared to localized vitiligo. Age of onset analysis of the disease suggests that the haplotypes: AACAT, AACCT, AATCC and AATCT had a profound effect in the early onset of the disease. Moreover, the analysis suggests that female patients had an early onset of vitiligo. Overall, our results suggest that TNF-α promoter polymorphisms may be genetic risk factors for susceptibility and progression of the disease. The up-regulation of TNF-α transcript and protein levels in individuals with susceptible haplotypes advocates the crucial role of TNF-α in autoimmune pathogenesis of vitiligo.

18 April 2012 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MIM. Imran
M. Imran
NLN.C. Laddha
N.C. Laddha
MDMitesh Dwivedi
Mitesh Dwivedi
MMM.S. Mansuri
M.S. Mansuri
JSJ. Singh
J. Singh
RBRasheedunnisa Begum
Rasheedunnisa Begum